Fertility and Sterility
Volume 92, Issue 1 , Pages 344-351 , July 2009

Biomarkers of ovarian function in girls and women with classic galactosemia

  • Rebecca D. Sanders, B.A.

      Affiliations

    • Graduate Program in Biochemistry, Cell, and Developmental Biology, Emory University School of Medicine, Atlanta, Georgia
    • ,
  • Jessica B. Spencer, M.D., M.Sc.

      Affiliations

    • Department of Gynecology and Obstetrics, Emory University School of Medicine, Atlanta, Georgia
    • ,
  • Michael P. Epstein, Ph.D.

      Affiliations

    • Department of Human Genetics, Emory University School of Medicine, Atlanta, Georgia
    • ,
  • Susan V. Pollak, B.A.

      Affiliations

    • Department of Obstetrics and Gynecology, Columbia University College of Physicians and Surgeons, New York, New York
    • ,
  • Pratibhasri A. Vardhana, M.D.

      Affiliations

    • Department of Obstetrics and Gynecology, Columbia University College of Physicians and Surgeons, New York, New York
    • ,
  • Joyce W. Lustbader, M.D.

      Affiliations

    • Department of Obstetrics and Gynecology, Columbia University College of Physicians and Surgeons, New York, New York
    • ,
  • Judith L. Fridovich-Keil, Ph.D.

      Affiliations

    • Department of Human Genetics, Emory University School of Medicine, Atlanta, Georgia
    • Corresponding Author InformationReprint requests: Judith L. Fridovich-Keil, Department of Human Genetics, Emory University School of Medicine, Atlanta, GA 30322 (FAX: 404 727-3949).

Received 28 February 2008 ,Revised 22 April 2008 ,Accepted 23 April 2008.

References 

  1. Fridovich-Keil J, Walter J. Galactosemia. In: D Valle, et al., eds. Online Metabolic and Molecular Bases of Inherited Disease—OMMBID. New York, McGraw-Hill, chap. 72, updated 2008. www.ommbid.com.
  2. Suzuki MWC, Beutler E. Large-scale molecular screening for galactosemia alleles in a pan-ethnic population. Hum Genet. 2001;109:210–215
  3. Welt C. Primary ovarian insufficiency: a more accurate term for premature ovarian failure. Clin Endocrinol (Oxf). 2008;68:499–509
  4. Waggoner DD, Buist NRM, Donnell GN. Long-term prognosis in galactosemia: results of a survey of 350 cases. J Inherit Metab Dis. 1990;13:802–818
  5. Guerrero NV, Singh RH, Manatunga A, Berry GT, Steiner RD, Elsas LJ. Risk factors for premature ovarian failure in females with galactosemia. J Pediatrics. 2000;137:833–841
  6. Forges T, Monnier-Barbarino P, Leheup B, Jouvet P. Pathophysiology of impaired ovarian function in galactosaemia. Hum Reprod Update. 2006;12:573–584
  7. Bosch AM, Grootenhuis MA, Bakker HD, Heijmans HSA, Wijburg FA, Last BF. Living with classical galactosemia: health-related quality of life consequences. Pediatrics. 2004;113:e423–e428
  8. Levy H, Driscoll S, Porensky R, Wender D. Ovarian failure in galactosemia. N Eng J Med. 1984;310:50
  9. Kaufman FR, Kogut MD, Donnell GN, Goebelsmann U, March C, Koch R. Hypergonadotropic hypogonadism in female patients with galactosemia. N Engl J Med. 1981;304:994–998
  10. Fraser IS, Russell P, Greco S, Robertson DM. Resistant ovary syndrome and premature ovarian failure in young women with galactosaemia. Clin Reprod Fertil. 1986;4:133–138
  11. Twigg S, Wallman L, McElduff A. The resistant ovary syndrome in a patient with galactosemia: a clue to the natural history of ovarian failure. J Clin Endocrinol Metab. 1996;81:1329–1331
  12. Lai KW, Cheng LYL, Cheung ALM, O WS. Inhibitor of apoptosis proteins and ovarian dysfunction in galactosemic rats. Cell Tiss Res. 2003;311:417–425
  13. Bandyopadhyay S, Chakrabarti J, Banerjee S, Pal AK, Bhattacharyya D, Goswami SK, et al. Prenatal exposure to high galactose adversely affects initial gonadal pool of germ cells in rats. Hum Reprod. 2003;18:276–282
  14. Chen YT, Mattison DR, Feigenbaum L, Fukui H, Schulman JD. Reduction in oocyte number following prenatal exposure to a diet high in galactose. Science. 1981;214:1145–1147
  15. Leslie ND, Yager KL, McNamara PD, Segal S. A mouse model of galactose-1-phosphate uridyl transferase deficiency. Biochem Mol Med. 1996;59:7–12
  16. Wehrli S, Reynolds R, Segal S. Evidence for function of UDP galactose pyrophosphorylase in mice with absent galactose-1-phosphate uridyltransferase. Mol Genet Metab. 2007;91:191–194
  17. Haberland C, Perou M, Brunngraber EG, Hof H. The neuropathology of galactosemia: a histopathological and biochemical study. J Neuropathol Exp Neurol. 1971;30:431–447
  18. Petry K, Greinix HT, Nudelman E, Eisen H, Hakomori S, Levy HL, et al. Characterization of a novel biochemical abnormality in galactosemia: deficiency of glycolipids containing galactose or N-acetylgalactosamine and accumulation of precursors in brain and lymphocytes. Biochem Med Metab Biol. 1991;46:93–104
  19. Charlwood J, Clayton P, Keir G, Mian N, Winchester B. Defective galactosylation of serum transferrin in galactosemia. Glycobiology. 1998;8:351–357
  20. Sturiale L, Barone R, Fiumara A, Perez M, Zaffanello M, Sorge G, et al. Hypoglycosylation with increased fucosylation and branching of serum transferrin N-glycans in untreated galactosemia. Glycobiology. 2005;15:1268–1276
  21. Jaeken J, Kint J, Spaapen L. Serum lysosomal enzyme abnormalities in galactosaemia. Lancet. 1992;340:1472–1473
  22. Prestoz L, Couto A, Shin Y, Petry K. Altered follicle stimulating hormone isoforms in female galactosaemia patients. Eur J Pediatr. 1997;156:116–120
  23. Barrios-De-Tomasi J, Timossi C, Merchant H, Quintanar A, Avalos JM, Andersen CY, et al. Assessment of the in vitro and in vivo biological activities of the human follicle-stimulating isohormones. Mol Cell Endocrinol. 2002;186:189–198
  24. Menezo Y, Lescaille M, Nicollet B, Servy E. Pregnancy and delivery after stimulation with rFSH of a galatosemia patient suffering hypergonadotropic hypogonadism: case report. J Assist Reprod Genet. 2004;21:89–90
  25. Visser J, Durlinger A, Peters I, van den Heuvel E, Rose U, Kramer P, et al. Increased oocyte degeneration and follicular atresia during the estrous cycle in anti-Müllerian hormone null mice. Endocrinology. 2007;148:2301–2308
  26. La Marca A, Stabile G, Carducci Artenisio A, Volpe A. Serum anti-Mullerian hormone throughout the human menstrual cycle. Hum Reprod. 2006;21:3103–3107
  27. Hehenkamp WJK, Looman CWN, Themmen APN, de Jong FH, te Velde ER, Broekmans FJM. Anti-Mullerian hormone levels in the spontaneous menstrual cycle do not show substantial fluctuation. J Clin Endocrinol Metab. 2006;91:4057–4063
  28. Tsepelidis S, Devreker F, Demeestere I, Flahaut A, Gervy C, Englert Y. Stable serum levels of anti-Mullerian hormone during the menstrual cycle: a prospective study in normo-ovulatory women. Hum Reprod. 2007;22:1837–1840
  29. Somunkiran A, Yavuz T, Yucel O, Ozdemir I. Anti-Mullerian hormone levels during hormonal contraception in women with polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol. 2007;134:196–201
  30. Wachs DS, Coffler MS, Malcom PJ, Chang RJ. Serum anti-Mullerian hormone concentrations are not altered by acute administration of follicle stimulating hormone in polycystic ovary syndrome and normal women. J Clin Endocrinol Metab. 2007;92:1871–1874
  31. Tano M, Minegishi T, Nakamura K, Karino S, Ibuki Y. Application of Chinese hamster ovary cells transfected with the recombinant human follicle-stimulating hormone (FSH) receptor for measurement of serum FSH. Fertil Steril. 1995;64:1120–1124
  32. Albanese C, Christin-Maitre S, Sluss PM, Crowley WF, Jameson JL. Development of a bioassay for FSH using a recombinant human FSH receptor and a cAMP responsive luciferase reporter gene. Mol Cell Endocrinol. 1994;101:211–219
  33. Gudermann T, Brockmann H, Simoni M, Gromoll J, Nieschlag E. In vitro bioassay for human serum follicle-stimulating hormone (FSH) based on L cells transfected with recombinant rat FSH receptor: validation of a model system. Endocrinology. 1994;135:2204–2213
  34. Tilly JL, Aihara T, Nishimori K, Jia XC, Billig H, Kowalski KI, et al. Expression of recombinant human follicle-stimulating hormone receptor: species-specific ligand binding, signal transduction, and identification of multiple ovarian messenger ribonucleic acid transcripts. Endocrinology. 1992;131:799–806
  35. La Marca A, Stabile G, Artenisio AC, Volpe A. Serum anti-Mullerian hormone throughout the human menstrual cycle. Hum Reprod. 2006;21:3103–3107
  36. Kaufman FR, Donnell GN, Roe TF, Kogut MD. Gonadal function in patients with galactosaemia. J Inherit Metab Dis. 1986;9:140–146
  37. Russell P, Bannatyne P, Shearman RP, Fraser IS, Corbett P. Premature hypergonadotropic ovarian failure: clinicopathological study of 19 cases. Int J Gynecol Pathol. 1982;1:185–201
  38. Knauff E, Richardus R, Eijkemans M, Broekmans F, de Jong F, Fauser B, et al. Heterozygosity for the classical galactosemia mutation does not affect ovarian reserve and menopausal age. Reprod Sci. 2007;14:780–785
  39. Cooper GS, Hulka BS, Baird DD, Savitz DA, Hughes CL, Weinberg CR, et al. Galactose consumption, metabolism, and follicle-stimulating hormone concentrations in women of late reproductive age. Fertil Steril. 1994;62:1168–1175
  40. Liu G, Shi F, Blas-Machado U, Duong Q, Davis VL, Foster WG, et al. Ovarian effects of a high lactose diet in the female rat. Reprod Nutr Devel. 2005;45:185–192
  41. Liu G, Shi F, Blas-Machado U, Yu R, Davis VL, Foster WG, et al. Dietary galactose inhibits GDF-9 mediated follicular development in the rat ovary. Reprod Toxicol. 2006;21:26–33
  42. Halperin J, Devi SY, Elizur S, Stocco C, Shehu A, Rebourcet D, et al. Prolactin signaling through the short form of its receptor represses FOXO3 and its target gene GALT causing a severe ovarian defect. Mol Endocrinol. 2008;22:513–522

 This work was supported by National Institutes of Health research grant nos. R01DK059904 (to J.L.F.-K.) and RO1DK063224 (to J.W.L). R.D.S. was supported in part by training grant no. 2T32GM008367-16 from the National Institutes of Health (B. Shur and K. Wilkinson, co-principal investigators).

 R.D.S. and J.B.S. contributed equally to this work.

 R.D.S. has nothing to disclose. J.B.S. has nothing to disclose. M.P.E. has nothing to disclose. S.V.P. has nothing to disclose. P.A.V. has nothing to disclose. J.W.L. has nothing to disclose. J.L.F.-K. has nothing to disclose.

PII: S0015-0282(08)00971-0

doi: 10.1016/j.fertnstert.2008.04.060

Fertility and Sterility
Volume 92, Issue 1 , Pages 344-351 , July 2009

Article Tools

* Image Usage & Resolution